Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
The British Journal of Diabetes & Vascular Disease
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Ubogagu, E.
Right arrow Articles by Feher, M. D
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Switching basal analogue insulins — short-term weight effects

Edith Ubogagu

Beta Cell Diabetes Centre, Chelsea and Westminster Hospital, NHS Foundation Trust, 369 Fulham Road, London, SW10 9NH

YP Samarasinghe

Beta Cell Diabetes Centre, Chelsea and Westminster Hospital, NHS Foundation Trust, 369 Fulham Road, London, SW10 9NH

Niel Munro

Beta Cell Diabetes Centre, Chelsea and Westminster Hospital, NHS Foundation Trust, 369 Fulham Road, London, SW10 9NH

Michael D Feher

Beta Cell Diabetes Centre, Chelsea and Westminster Hospital, NHS Foundation Trust, 369 Fulham Road, London, SW10 9NH, michael.feher{at}chelwest.nhs.uk

Efforts to improve glycaemic control in people with diabetes have encouraged more intensive therapeutic approaches. Hypoglycaemia is a risk associated with insulin therapy and a further consequence of intensified treatment is unwanted weight gain. The introduction of the long-acting insulin analogues, glargine and detemir, has provided a circulating insulin profile more reminiscent of normal basal insulin. This has allowed insulin dose escalation with a reduced risk of hypoglycaemia. The current study investigates the effect of switching treatment to insulin detemir in patients who had gained weight on insulin glargine therapy. Two months of treatment with insulin detemir did not alter glycaemic control or insulin dosage, but body weight was significantly reduced in patients with type 1 (p<0.05) and type 2 (p<0.005) diabetes. Br J Diabetes Vasc Dis 2008; 8: 183—186

Key Words: detemir • glargine • insulin analogues • weight gain

The British Journal of Diabetes & Vascular Disease, Vol. 8, No. 4, 183-186 (2008)
DOI: 10.1177/1474651408094846
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?